SCHEMBL7799355

SCHEMBL7799355

CCN(CC)C(=O)c1cnc2c3c(ccc2c1)C(=O)C(C(=O)O)C=N3

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.34
ALDH1A1 P00352 5/20 0.34
LMNA P02545 3/20 0.34
CFTR P13569 1/20 0.34
FGFR1 P11362 2/20 0.33
SRC P12931 2/20 0.33
KDR P35968 1/20 0.33
MAPT P10636 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
GRM5 P41594 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
HSP90AA1 P07900 2/20 0.32
HSP90AB1 P08238 2/20 0.32
RECQL P46063 1/20 0.32
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
OPRD1 P41143 1/20 0.30
KCNH2 Q12809 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8437417 0.94 HCAR3 (0.33) HPGDALDH1A1LMNACFTRFGFR1
SCHEMBL7801055 0.92 HPGD (0.39) HPGDALDH1A1LMNACFTRMAPT
SCHEMBL7801069 0.90
SCHEMBL7801071 0.88 LRRK2 (0.33)
SCHEMBL7799131 0.86 PDK2 (0.36) HPGDALDH1A1LMNAKDRMAPT
SCHEMBL6981270 0.84 PSMD14 (0.43)
SCHEMBL7799119 0.83 MEN1 (0.43) HPGDALDH1A1CFTRMEN1KMT2A
SCHEMBL7793465 0.82 TP53 (0.36) HPGDALDH1A1LMNAMAPTMEN1
SCHEMBL6984771 0.82 PSMD14 (0.43) SMN1; SMN2
SCHEMBL7802386 0.81 KMT2A (0.40) ALDH1A1LMNAMAPTTDP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-1999021860-B1 PHENANTHROLINE DERIVATIVES FIBROGEN INC (US) 1999-08-05 WO claimed
US-20010001101-A1 Phenanthroline derivatives ZENECA LIMITED 2001-05-10 US disclosed
EP-1027351-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 2000-08-16 EP disclosed
US-5916898-A ANTIFIBROPROLIFERTIVE, ENZYME INHIBITORS OF PYROLYL 4-HYDROXYLASE, ANTIARTHRITIC AGENTS ZENECA LIMITED (GB) 1999-06-29 US disclosed
WO-1999021860-A1 PHENANTHROLINE DERIVATIVES FIBROGEN, INC. (US) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010001101-A1 Phenanthroline derivatives H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, COL1A1, COL2A1 HPGD 802/4885ALDH1A1 425/4885LMNA 396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.